期刊文献+

Transdermal Fentanyl for Management of Cancer Pain in Elderly Patients in China 被引量:2

芬太尼透皮贴剂治疗老年癌痛病人(英文)
下载PDF
导出
摘要 Objective: Objective: To assess the effect and adverse effects of transdermal fentanyl for elderly patients with cancer pain in China. Methods: A total of 1664 elderly patients (aged 65-90 with mean age of 72.6) with cancer pain enrolled in the multicenter study from 136 institutes in China. Of them, 408 (28.8%) patients were 75 years old or older. All patients received transdermal fentanyl for the management of cancer pain. The patients were asked to record the attacks of pain, quality of life, and any side effects of the treatment. Results: Baseline mean of pain intensity was 7.34. On day 1, 3, 6, 9 15, and 30, the pain mean scores were decreased to 3.82, 2.80, 2.43, 2.11, 1.83, 1.64 (P=0.000). The effective rate was 97.18%. The mean doses of fentanyl was 31.34 g/h (25-150 g/h) initially, and 40.59 g/h and 47.50 g/h (25-200 g/h) at day 15 and day 30. At treatment day 15, the dose of fentanyl was ranger from 25 to 50 g/h in 91.8% of patients, 75 to 100 g/h in 7.5% patients, and 125 to 200 g/h only in 0.8% patients. The fine quality of life was in 25.4% patients before treatment, and was 71.15% and 73.04% at day 15 and day 30 respectively (P=0.0000). The common side effects were constipation (10.70%), nausea (11.96%), dizzy (6.85%), vomiting (3.85%), sedation (2.40%), Respiratory depression (0.12%). 86.2% patients preferred continue treated by transdermal fentanyl. Conclusions: Transdermal fentanyl for the elderly with cancer pain is effective, safe, convenient, and can improve the quality of life. Transdermal fentanyl can be recommended as a first-line drug for the treatment of elderly patients with moderate to severe cancer pain, and the initial doses is recommended as 25 g/h.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2004年第2期85-89,125,共6页 中德临床肿瘤学杂志(英文版)
关键词 ELDERLY cancer pain transdermal fentanyl pain management 芬太尼 透皮贴剂 老年人 癌痛 不良反应
  • 相关文献

同被引文献7

  • 1李琼,吴明富,宋安萍,魏军成,徐刚,卢运萍,马丁.浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J].癌症,2006,25(3):363-366. 被引量:53
  • 2Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity [J]. Clin Cancer Res, 2010, 12 (20 Pt 2) : 6243s-6249s. 被引量:1
  • 3刘鲁川.麻醉药品临床使用与规范化管理培训教材[M].北京:红旗出版社,2005:99. 被引量:1
  • 4Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain [J]. Cancer Res, 2010, 61 (10) : 4038-4047. 被引量:1
  • 5Faeehini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronie aeid is inversely correlated to skeletal related events (SRE) [J]. J Exp Clin Cancer Res,2010,26(3): 307-312. 被引量:1
  • 6Coleman RE. Metastatic bone disease: clinical features, pathophysi- ology and treatment strategies [J]. Cancer Treat Rev, 2012,27 (2) : 165-176. 被引量:1
  • 7Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site [J]. Psyehooneology, 2001,10 (1) : 19-28. 被引量:1

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部